Tradestie Institutional Equity Comparison Engine
AURA vs MPLT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AURA Overall Edge
AURA Captures Institutional Edge (3โ0 Pillars ยท 4โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aura Biosciences, Inc. Common Stock (AURA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AURA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MPLT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro) against MPLT sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
AURA N/M vs MPLT N/M Fwd P/E
Growth & Margin Winner
AURA
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
AURA
1Y +30.4% vs -51.4% ยท 52W Pos 52% vs 3%
Options & Structure Winner
AURA
CONSOLIDATION (22nd %ile IV) vs BREAKDOWN (8th %ile IV)
AURA
NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap
$728.6M
1M Return
+18.2%
1Y Return
+30.38%
Forward P/E
N/M
Unified AI Score
31.1 / 100
SELL
Tech 8.0
Fund 39.0
Flow 71.0
Mom 44.0
MPLT
US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$6.94
-4.28% 1D
Market Cap
$392.9M
1M Return
-9.87%
1Y Return
-51.4%
Forward P/E
N/M
Unified AI Score
50.4 / 100
HOLD
Tech 49.0
Fund 56.0
Flow 64.0
Mom 58.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AURA +30.38%
MPLT -51.4%
Spread: +81.78 pp (AURA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
AURA TTM Op. Margin: 0.0%
MPLT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs MPLT. Trailing 12-month operating profitability (AURA 0.0% vs MPLT 0.0%) and valuation multiples (AURA N/M vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AURA | MPLT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $728.6M | $392.9M | Larger Scale | AURA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -61.7% | -111.5% | Higher ROE | AURA |
| 52-Week Range Position Momentum | 52% ($5โ$10) | 3% ($6โ$40) | Stronger Trend | AURA |
| Beta / 30D Volatility Risk Regime | 0.92ฮฒ ยท 75% Vol | 1.05ฮฒ ยท 78% Vol | Lower Realized Risk | AURA |
| Unified Institutional Score Composite Signal | 31.1 / 100 (SELL) | 50.4 / 100 (HOLD) | Higher Composite | MPLT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AURA vs MPLT Buy Guide
AURA
CONSOLIDATION
135d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
MPLT
BREAKDOWN
144d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AURA nor MPLT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.